Cancer is a significant opportunity for the development of tissue engineering and cell therapies, but it is more than just an opportunity currently, since many companies are active and the market for cancer cell/tissue therapies already stands at nearly $500 million.
Currently, OSI Pharmaceuticals has a commanding lead in this area, with its Tarceva being [...]
The global market for coronary stents is estimated to be in excess of $7 billion and projected to be growing at 6% per year. With the average age of citizens in developed countries increasing, there is an increased need to provide medical care to the average citizen. As such, an aging population translates into increasing [...]
Our research into the products, technologies, companies and markets for tissue engineering and cell therapy has revealed that the 2009 market was at $6.9 billion. The market has grown dramatically, in commercialized products and company activity, over the past few years and is on an accelerated growth rate as technology hurdles are overcome and clinical [...]
The number of competitors developing and marketing cell therapy and tissue engineering products is extraordinary. But since approved clinical applications are proliferating and the resulting market has been driving dramatic double-digit-plus growth, it's unsurprising that competitors from extreme sides of the medical technology industry — drug, device, and biotech — are converging on this lucrative [...]
The number of companies with approved products and measurable revenues in the field of cell therapy and tissue engineering has exceeded the expectation of many (though not all) in the industry.
Markets such as cell/tissue are often characterized by overestimated evaluations of commercial potential and underestimated consideration of the actual challenges. Indeed many technology challenges remain [...]
Market drivers that vary geographically account for some big differences in the distribution of the coronary stent market across the currently available stent types, and these differences will continue when bioabsorbable stents (and others) are introduced to the market over the next few years.
The local market forces dictating these differences include:
Regulatory timelines in one market [...]
One of the key areas of interest for development of products in surgical sealing, closure and hemostasis is in neural tissue surgery, encompassing chronic stroke, spinal cord trauma, neurovascular defects, and brain tumor treatments. In the U.S. alone, there were some 5.6 million patients in this category in 2008 who could benefit from these products.
The [...]
In treatment of acute and chronic wounds, the advanced wound technologies developed by manufacturers provide benefits that facilitate healing, minimize infection and provide other benefits toward reduced cost, less pain, faster healing and combinations of these and other benefits. Advanced products in wound care include film dressings, hydrocolloids, foam dressings, alginate dressings, hydrogels, non-adherent dressings, [...]
Advanced wound management technologies — those used in the clinical management of wounds (not OTC) — represent a $5 billion global market that will triple in the next ten years. These technologies have continued to evolve beyond simple dressings and bandages to be able to accelerate wound healing, improve clinical outcomes and, in particular, attempt [...]
Products for the treatment of wounds can be divided into categories using a number of different classification systems. For the sake of analysis (as applied in the MMD report #S247), products and technologies in wound management can be divided generally into traditional products (simple bandages, dressings and closures) and advanced wound management. The advanced area [...]
Contact:
